From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Canadian Government Awards Xagenic for POC Diagnostic Platform

by Global Biodefense Staff
February 21, 2013

The Government of Canada has awarded Xagenic, Inc., a privately held Toronto-based company, an investment contract to support further development of a lab-free, point-of-care (POC) molecular diagnostic platform with a 20-minute time to result. 

Xagenic will receive up to $990,000 CAD in funding from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario).  The effort is part of the “Investing in Business Innovation” initiative, designed to boost private sector investment in Canadian start-up businesses to accelerate the development of new products, processes and practices and bring them to market. 

The announcement was made in the keynote speech at the Conference Board of Canada’s Business Innovation Summit 2013 in Toronto this week. 

“This investment from FedDev complements our $10M Series A venture capital round, which included investments from CTI Life Sciences Fund, the Ontario Emerging Technologies Fund (OETF) and QIAGEN N.V.”, said Shana Kelley, Chief Technology Officer of Xagenic.  “In the current environment, financial support from the Government enhances our capabilities to develop cutting edge technologies that improve patient care,” added the company’s Director of Business Development, Ihor Boszko. 

The company’s fully automated technology platform is based on ultrasensitive microelectrode arrays. Nanostructured sensors, coupled with highly amplified signals that are generated by an electrocatalytic reporter system, allow direct analysis of clinical samples. The technology is highly versatile and has been validated with a variety of targets, cell types, and specimen types. It provides rapid (15-20 minute) sample-to-answer diagnostic test results with nucleic acid amplification test (NAAT)-like performance.

Because the system does not rely on optical detection components or enzymatic amplification, crude samples can be analyzed with minimal sample processing. Xagenic is currently developing infectious disease diagnostic tests that will allow the detection of a variety of analytes on the platform in situations where rapid test turnaround will provide clinically actionable results that dramatically improve patient care.  

Source: PRNewswire, Xagenic

From Our Partners
Tags: AwardsNanotechPOC Diagnostics

Related Posts

Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC